The potential of Alzheimer's treatments
This article was originally published in Scrip
Executive Summary
Recent clinical research in Alzheimer's disease is best-known for numerous high-profile failures of would-be blockbuster drugs. But behind the headlines, promising biomarker research is beginning to surpass the development of new disease-modifying therapies. Daniel Chancellor argues that a battery of diagnostic tests may allow for earlier intervention and better treatment outcomes.